Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
What the Research Actually Shows Published research on AOD-9604 describes: Modest body fat reduction in preclinical and early clinical settings Reduced triglycerides in some studies Minimal effect on IGF-1 confirmed across the clinical dataset Good tolerability adverse event rates in the phase 2 obesity trials were comparable to placebo Variable weight loss some patients respond better than others, consistent with many metabolic interventions The effect size in phase 2 obesity trials was modest typically in the range of a few pounds over the study period
Evening administration aligns with the pineal gland's natural circadian activity
Most scientific results come from the study of its effects in rodents
PMID: 39607791
Call 813-279-2211 Learn more at Envizion Medical
Pull the calculated volume corresponding to the target dose (1 mcg/kg to 10 mcg/kg) into an insulin syringe (28 to 31 gauge) to minimize tissue trauma at the injection site
US$ 29.34
US$ 24.67
US$ 21.13
